

# The Kidney–Gut Axis: Implications for Nutrition Care

Megan Rossi, BSc (Hons),<sup>\*,†,‡</sup> David W. Johnson, MBBS, PhD, PSM,<sup>†,‡,¶</sup>  
and Katrina L. Campbell, PhD<sup>\*,‡,§</sup>

There is increasing clinical evidence that patients with chronic kidney disease (CKD) have a distinctly dysbiotic intestinal bacterial community, termed the gut microbiota, which in turn drives a cascade of metabolic abnormalities, including uremic toxin production, inflammation, and immunosuppression, that ultimately promotes progressive kidney failure and cardiovascular disease. As the gut microbiota is intimately influenced by diet, the discovery of the kidney–gut axis has created new therapeutic opportunities for nutritional intervention. This review discusses the metabolic pathways linking dysbiotic gut microbiota with adverse health outcomes in patients with CKD, as well as novel therapeutic strategies for targeting these pathways involving dietary protein, fiber, prebiotics, probiotics, and synbiotics. These emerging nutritional interventions may ultimately lead to a paradigm shift in the conventional focus of dietary management in CKD.  
© 2015 by the National Kidney Foundation, Inc. All rights reserved.

## Introduction

IN THE PAST 5 years there have been significant scientific developments linking gut health and several chronic diseases,<sup>1</sup> including kidney disease.<sup>2</sup> Indeed, recent findings have implicated the community of bacteria that reside in the large bowel, termed the gut microbiota, as a key player in the heightened risks of kidney failure progression and cardiovascular disease observed in patients with chronic kidney disease (CKD).<sup>3</sup> The gut microbiota is not only highly dependent on diet, but its plasticity makes it an attractive therapeutic target for dietary manipulation.<sup>4</sup> Therefore, the emerging role of gut health in CKD, which has been coined the “kidney–gut axis,” is of significant importance to the dietetic community. The aim of this article is to describe the link between diet, gut microbiota, and clinical outcomes in CKD patients and then outline novel dietary interventions in the area of gut health.

## Diet and CKD: The Origins and Link to Gut Health

A person’s risk for CKD is determined by both genetic and environmental factors.<sup>5</sup> The significant rise in the prevalence

of kidney disease within a single generation suggests a dominant role of environment in promoting CKD. One of the largest environmental factors a person is exposed to is what they eat. However, until recently, our understanding of the role of diet as an environmental risk factor has been restricted to its effect on human metabolism, without due consideration of its effect on intestinal bacterial metabolism and ensuing consequences for human health. The recent discovery of the gut microbiota’s metabolic potential, which contains 100 times the genetic material of mammalian cells,<sup>6</sup> has uncovered a new pathway in which the diet can impact on health and disease (illustrated in Fig. 1). The implications of this in CKD are significant, with a number of studies demonstrating a distinct dysbiotic gut microbiota in this population.<sup>7,8</sup> Moreover, dietary recommendations in CKD may indirectly contribute to this dysbiosis, particularly in patients prescribed oxalate- and potassium-restricted diets.<sup>9</sup>

## Diet–Gut Interaction

Dietary constituents that are not absorbed in the small intestine are rapidly fermented by the colony of bacteria in the large intestine. The two main types of bacterial fermentation are saccharolytic (carbohydrate) and proteolytic (protein). Saccharolytic is a more favorable type of fermentation because of the beneficial metabolites that it forms, including short chain fatty acids butyrate, propionate, and acetate.<sup>10</sup> These short chain fatty acids are not only integral to the health of the colonic epithelium, but have a myriad of other benefits, including anti-inflammatory properties.<sup>11</sup> Proteolytic fermentation, on the other hand, is known to be the source of a number of potentially toxic metabolites, particularly the key nephrovascular uremic toxins, indoxyl sulfate and p-cresyl sulfate.<sup>12</sup> The relative amount of saccharolytic versus proteolytic fermentation that occurs in the colon is intimately regulated by dietary nutrient availability, particularly the ratio of carbohydrate to nitrogen (protein) and colonic transit time.<sup>13</sup>

\*Department of Nutrition and Dietetics, Princess Alexandra Hospital, Brisbane, Australia.

†School of Medicine, University of Queensland, Brisbane, Australia.

‡Translational Research Institute, Brisbane, Australia.

§Faculty of Health Sciences and Medicine, Bond University, Robina, Australia.

¶Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.


Financial Disclosure: The authors declare that they have no relevant financial interests.

Address correspondence to Megan Rossi, BSc (Hons), Department of Nutrition and Dietetics, Building 15, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia. E-mail: [megan.rossi@health.qld.gov.au](mailto:megan.rossi@health.qld.gov.au)

© 2015 by the National Kidney Foundation, Inc. All rights reserved.

1051-2276/\$36.00

<http://dx.doi.org/10.1053/j.jrn.2015.01.017>



**Figure 1.** Two pathways in which diet can impact on disease.

### Dietary Fiber

Dietary fiber is a broad term encompassing carbohydrates that are indigestible by human alimentary enzymes.<sup>14</sup> CODEX Alimentarius Commission recently adopted a comprehensive definition of dietary fiber, categorizing different types by their molecular weight and solubility (Fig. 2). There are a number of well-established benefits associated with dietary fiber, including reductions in total cholesterol and postprandial blood glucose levels.<sup>15</sup> Some of these benefits overlap between different types of dietary fiber, whereas others appear to be category specific. Nonetheless, there is currently insufficient evidence to suggest one type of fiber is superior to another and therefore the concept of “all fiber fits” to achieve the Dietary Reference Values is recommended.<sup>16</sup>

Dietary fiber may assume even greater importance in CKD patients based on additional benefits with respect to enhanced integrity of the gastrointestinal wall<sup>17</sup> (which

has been shown to be “leaky” in CKD<sup>18</sup>) and reduced systemic levels of hazardous uremic toxins.<sup>19</sup> Furthermore, an analysis of 14,543 participants in the National Health and Nutrition Examination Survey III demonstrated that increases in dietary fiber intake were associated with statistically significant and clinically important reductions in inflammation and mortality in people with kidney disease and that these benefits were significantly more marked than those observed in patients without kidney disease.<sup>20</sup> Despite these findings, there is limited evidence from intervention studies, which have led to weak dietary fiber recommendations in renal nutrition guidelines.<sup>9</sup> There is, therefore, a clear need for further research investigating the role of dietary fiber in CKD. Additionally, there are a number of other aspects that dietitians need to consider when recommending dietary fiber in practice. These are summarized in Table 1.

### Dietary Protein


There are a number of factors that impact on the availability of protein in the colon leading to increased proteolytic fermentation, including the efficiency of protein assimilation in the small intestine and colonic transit time. Protein assimilation in the small intestine is affected by protein load (amount), form (cooked or uncooked), and source (animal or plant),<sup>21</sup> as well as the presence of other dietary constituents (eg, resistant starch).<sup>22</sup> The impact of these variables can be significant, with studies in the healthy population demonstrating protein malabsorption of up to 35%.<sup>23</sup> In the CKD population, protein assimilation is known to be further impaired,<sup>24</sup> with a range of mechanisms thought to contribute, including acid suppression therapy,<sup>25</sup> gastroparesis, small-bowel bacterial overgrowth, and pancreatic abnormalities.<sup>26</sup>

Increased colonic transit time is another common symptom in patients with CKD, often secondary to patients’ medical treatment.<sup>27</sup> Common factors likely to contribute include fluid restriction, medication load (including phosphate binders), and dietary restriction, particularly of higher fiber foods.

Targeting modifiable predictors of protein assimilation and delayed colonic transit time, in order to lower proteolytic fermentation, maybe a valuable, yet to date an under-researched strategy to improve gut health in CKD.

### Targeting the Gut in CKD

The concept of using the gastrointestinal tract to treat kidney disease is not new in nephrology. The idea was first conceived by a Roman physician, Pedanius Dioscorides, over 2000 years ago as a means to eliminate toxin accumulation in kidney disease.<sup>28</sup> There have subsequently been a number of attempts to use the gut in CKD, including enteric intestinal dialysis,<sup>29</sup> yet the therapies’ invasive nature coupled with limited knowledge, has inhibited translation in practice. It is only in recent years, with high throughput



**Figure 2.** Dietary fiber categories.

**Table 1.** Points to Consider When Recommending Dietary Fiber in Practice

Points to Consider	Implications for Practice
Fiber content of food can be high variable based on different cooking and processing techniques (particularly in resistant starch)	Should we be encouraging specific cooking and cooling techniques?
Most countries' nutrient composition tables are out dated where dietary fiber estimates do not include important subcategories of resistant starch and low molecular weight oligosaccharides <sup>43</sup>	Are we under estimating the fiber benefits of some foods?
The latest Codex definition recognizes all substances that behave like fiber, regardless of how they are produced, should be considered as important sources of dietary fiber if they show physiological benefits	Fortification of food products with dietary fiber may be an important source for patients with chronic kidney disease who need to restrict some naturally occurring sources, such as in the case of hyperkalemia
Traditional "renal diets" are inherently lower in fiber based on potassium and oxalate restrictions	It is important to ensure patients are still receiving adequate dietary fiber when prescribing potassium- and oxalate-restricted diets

technologies providing a better understanding of the metabolic potential of the gut microbiota, that therapies targeting the gut are being revived in CKD.

There have been a number of drug therapies proposed to modify gut microbial metabolism, including alpha glucosidase inhibitors<sup>30</sup> and antibiotics,<sup>31</sup> however, diet-based interventions, given their typical innocuous nature, maybe a more attractive target.

### Pre- and Probiotics in CKD

Prebiotics, the "indigestible" carbohydrates that stimulate bacteria, and probiotics, the live beneficial bacteria (such as *Bifidobacterium*), have been consumed as part of the diet of many cultures for thousands of years.<sup>32</sup> These naturally occurring components in health-promoting foods, described in Table 2, have more recently been cultivated by industry and are now widely available as commercial supplements and are in many fortified foods. A comprehensive product update on probiotics was recently provided by Zirker.<sup>33</sup>

Characterization of the dysbiotic gut microbiota in CKD provides a mechanistically sound rationale for the potential benefit of pre- and probiotics to re-establish microbial balance. There is a growing body of supportive evidence surrounding this therapy for targeting a wide range of common disturbances in CKD.<sup>34</sup> A summary of the potential benefits of pre- and/or probiotic supplementation, as well as their hypothesized mechanisms of action, is listed in Table 3. Extrapolation of findings from non-CKD clinical trials also suggest a number of other potential benefits for this therapy relevant in CKD such as blood glucose control,<sup>35</sup> hypertension,<sup>36</sup> weight management,<sup>37</sup> and urinary tract infections.<sup>38</sup>

Given the infancy of this area of research most of the proof-of-concept studies have relied on commercial supplements to provide precise and high dose quantities of pre- and probiotics. However, one of the fundamental principles of dietetic practice is to recommend nutrients from food sources as first line therapy, and it is only when this fails that supplements are used. This concept may also

**Table 2.** Naturally Occurring Sources of Pre- and Probiotics

Probiotic "Live microorganisms which when administered in adequate amounts confer a health benefit on the host" <sup>44</sup>		Prebiotics "A selectively fermented ingredient that allows specific changes, both in the composition and/or activity in the gastrointestinal microflora that confers benefits upon host wellbeing and health" <sup>45</sup>	
Food Source	Predominant Type*	Food Source	Predominant Type
Yogurts (fermented milk product)	Started cultures <i>Lactobacillus bulgaricus</i> and <i>Streptococcus thermophilus</i> <sup>46</sup>	Asparagus	Inulin <sup>47</sup>
Kefir (fermented milk beverage)	<i>Lactobacillus</i> and <i>Lactococcus</i> genera, and yeast <sup>48</sup>	Rye bread	Inulin <sup>47</sup>
Kombucha (tea)	<i>Gluconacetobacter</i> , <i>Lactobacillus</i> and <i>Zygosaccharomyces</i> (yeast) <sup>49</sup>	Canned beans	GOS <sup>50</sup>
Kimchi and Sauerkraut	<i>Leuconostoc</i> , <i>Lactobacillus</i> , <i>Pediococcus</i> and <i>Streptococcus</i> genera <sup>51</sup>	Lentils	GOS <sup>50</sup>
Natto (fermented soy beans)	<i>Bacillus subtilis</i> specie <sup>52</sup>	Nectarines	FOS <sup>53</sup>

FOS, fructo-oligosaccharides; GOS, galacto-oligosaccharide.

\*The bacterial profile can differ depending on varieties, raw materials used, process, fermentation, and preservation methods.

**Table 3.** Target Treatment and Proposed Mechanisms of Pre- and/or Probiotic Supplementation in Patients with Established Chronic Kidney Disease

Observed Benefit	Proposed Mechanisms
↓ Fecal vancomycin-resistant enterococci <sup>54</sup>	- Competitive colonization - Antimicrobial production ↓ Colonic pH
↑ Serum folate <sup>55</sup>	↑ Bacterial production of folate
↓ Serum uremic toxins ■ Urea <sup>56</sup> ■ Uric acid <sup>57</sup> ■ Indoxyl sulfate <sup>58</sup> ■ p-Cresyl sulfate <sup>59</sup> ■ Di-methylamine <sup>60</sup>	- ↑ Microbial metabolism - Competitive colonization - Antimicrobial production - ↓ Colonic pH - ↓ Colonic transit time - ↓ Availability of substrate ↓ Colonic pH ↑ the ionization of Ca which bind with intestinal phosphorus ions as an intrinsic binder
↓ Serum phosphate <sup>61</sup>	↑ Bacterial production of nicotinic acid
↓ Serum triglycerides <sup>55</sup>	↑ Bacterial production of B vitamins
↓ Serum homocysteine <sup>55</sup>	↓ Symptoms of uremia
↑ Quality of life <sup>62</sup>	↑ Microbial metabolism of oxalate
↓ Urinary oxalate <sup>63</sup>	

translate to pre- and probiotics with support for the benefits of naturally occurring probiotics in animal models demonstrating foods such as kefir,<sup>39</sup> koumiss, and yoghurt<sup>39,40</sup> were able to improve renal injury. However, whether this translates *in vivo* is the source of ongoing debate with conflicting studies suggesting foods sources of probiotics are less effective when compared to commercial probiotic capsules based on their bile and acid resistance.<sup>41,42</sup>

Despite the growing interest and potential in CKD for pre- and probiotics (both commercial and natural sources), this area of research is in its infancy and further high quality clinical trials are needed before translation can occur.

### Practical Application

There is evolving evidence implicating diet and its impact on colonic bacterial metabolism in the heightened risks of kidney failure progression and cardiovascular disease in CKD patients. This article presented a number of emerging concepts linking the diet and gut microbiota dysbiosis in CKD, with suggestions for how this may impact future clinical practice and ultimately lead to a paradigm shift in the focus of dietary advice in CKD, particularly with respect to fiber, protein, and pre-/probiotics.

### Acknowledgments

M. Rossi is a recipient of the Princess Alexandra Private Practice Trust Fund postgraduate scholarship. K. L. Campbell is supported by a Queensland Government, Health and Medical Research Health Research Fellowship, and a Lions Senior Medical Research Fellowship. D. W. John-

son is also supported by a Queensland Government, Health and Medical Research Health Research Fellowship.

### References

1. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. *Physiol Rev*. 2010;90:859-904.
2. Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. *Nephrol Dial Transplant*. 2011;26:759-761.
3. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. *J Am Soc Nephrol*. 2014;25:657-670.
4. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014;505:559-563.
5. Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. *Nephron Clin Pract*. 2011;118:c269-c277.
6. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486:207-214.
7. Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. *Am J Nephrol*. 2014;39:230-237.
8. Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. *Kidney Int*. 2013;83:308-315.
9. Ash S, Campbell KL, Bogard J, Millichamp A. Nutrition prescription to achieve positive outcomes in chronic kidney disease: a systematic review. *Nutrients*. 2014;6:416-451.
10. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol*. 2006;40:235-243.
11. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. *Nutrients*. 2011;3:858-876.
12. Rossi M, Campbell KL, Johnson DW. Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. *OA Nephrology*. 2013;1:13.
13. Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. *Kidney Int Suppl*. 2009;76:S12-S19.
14. Prosky L. What is dietary fiber? *J AOAC Int*. 2000;83:985-987.
15. Howlett JF, Betteridge VA, Champ M, Craig SA, Meheust A, Jones JM. The definition of dietary fiber—discussions at the Ninth Vahouny Fiber Symposium: building scientific agreement. *Food Nutr Res*. 2010;54:1-9.
16. Jones JM. CODEX-aligned dietary fiber definitions help to bridge the 'fiber gap'. *Nutr J*. 2014;13:34.
17. Burger-van Paassen N, Vincent A, Puiman PJ, et al. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. *Biochem J*. 2009;420:211-219.
18. McIntyre CW, Harrison LE, Eldehni MT, et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. *Clin J Am Soc Nephrol*. 2011;6:133-141.
19. Birkett A, Muir J, Phillips J, Jones G, O'Dea K. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. *Am J Clin Nutr*. 1996;63:766-772.
20. Krishnamurthy VM, Wei G, Baird BC, et al. High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. *Kidney Int*. 2012;81:300-306.
21. Gilani GS, Cockell KA, Sepehr E. Effects of antinutritional factors on protein digestibility and amino acid availability in foods. *J AOAC Int*. 2005;88:967-987.
22. Silvester KR, Cummings JH. Does digestibility of meat protein help explain large bowel cancer risk? *Nutr Cancer*. 1995;24:279-288.
23. Evenepoel P, Claus D, Geypens B, et al. Amount and fate of egg protein escaping assimilation in the small intestine of humans. *Am J Physiol*. 1999;277(5 Pt 1):G935-G943.

24. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. *Kidney Int.* 2003;64:2196-2203.
25. Evenepoel P, Claus D, Geypens B, et al. Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. *Aliment Pharmacol Ther.* 1998;12:1011-1019.
26. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. *Am J Clin Nutr.* 2004;80:1536-1543.
27. Strid H, Simren M, Johansson AC, Svedlund J, Samuelsson O, Bjornsson ES. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. *Nephrol Dial Transpl.* 2002;17:1434-1439.
28. Haas LF. Pedanius Dioscorides (born about AD40, died about AD90). *J Neurol Neurosurg Psychiatry.* 1996;60:427.
29. Twiss EE, Kolff WJ. Treatment of uremia by perfusion of an isolated intestinal loop; survival for forty-six days after removal of the only functioning kidney. *J Am Med Assoc.* 1951;146:1019-1022.
30. Su B, Liu H, Li J, et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. [published online ahead of print October 18 2014]. *J Diabetes.* 2014. <http://www.ncbi.nlm.nih.gov/pubmed/25327485>. Accessed November 24, 2014.
31. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol.* 2008;6:e280.
32. Chow J. Probiotics and prebiotics: a brief overview. *J Ren Nutr.* 2002;12:76-86.
33. Zirker L. Probiotic use in chronic kidney disease patients. *J Ren Nutr.* 2014;24:e47-e49.
34. Poesen R, Meijers B, Evenepoel P. The colon: an overlooked site for therapeutics in dialysis patients. *Semin Dial.* 2013;26:323-332.
35. Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. *Br J Nutr.* 2014;111:1147-1161.
36. Dong JY, Szeto IM, Makinen K, et al. Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials. *Br J Nutr.* 2013;110:1188-1194.
37. Sanchez M, Darimont C, Drapeau V, et al. Effect of *Lactobacillus rhamnosus* CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. *Br J Nutr.* 2014;111:1507-1519.
38. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B. Oral probiotics can resolve urogenital infections. *FEMS Immunol Med Microbiol.* 2001;30:49-52.
39. Punaro GR, Maciel FR, Rodrigues AM, et al. Kefir administration reduced progression of renal injury in STZ-diabetic rats by lowering oxidative stress. *Nitric Oxide.* 2014;37:53-60.
40. Sari EK, Bakir B, Aydin BD, Sozmen M. The effects of kefir, koumiss, yogurt and commercial probiotic formulations on PPARalpha and PPAR-beta/delta expressions in mouse kidney. *Biotech Histochem.* 2014;89:287-295.
41. Dheer R, Chordia T, Pechenyak B, et al. Kibow biotics is preferred and superior to yogurt for uremia applications. *J Am Soc Nephrol.* 2004;15:769A.
42. Saxelin M, Lassig A, Karjalainen H, et al. Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese. *Int J Food Microbiol.* 2010;144:293-300.
43. Westenbrink S, Brunt K, van der Kamp JW. Dietary fibre: challenges in production and use of food composition data. *Food Chem.* 2013;140:562-567.
44. Organization FaA. *Guidelines for the evaluation of probiotics in food. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food.* London: Food and Agriculture Organization; 2002.
45. Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutr Res Rev.* 2004;17:259-275.
46. Elli M, Callegari ML, Ferrari S, et al. Survival of yogurt bacteria in the human gut. *Appl Environ Microbiol.* 2006;72:5113-5117.
47. Muir JG, Shepherd SJ, Rosella O, Rose R, Barrett JS, Gibson PR. Fructan and free fructose content of common Australian vegetables and fruit. *J Agric Food Chem.* 2007;55:6619-6627.
48. Lopitz-Otsoa F, Rementeria A, Elguezabal N, Garaizar J. Kefir: a symbiotic yeasts-bacteria community with alleged healthy capabilities. *Rev Iberoam Micol.* 2006;23:67-74.
49. Marsh AJ, O'Sullivan O, Hill C, Ross RP, Cotter PD. Sequence-based analysis of the bacterial and fungal compositions of multiple kombucha (tea fungus) samples. *Food Microbiol.* 2014;38:171-178.
50. Biesiekierski JR, Rosella O, Rose R, et al. Quantification of fructans, galacto-oligosaccharides and other short-chain carbohydrates in processed grains and cereals. *J Hum Nutr Diet.* 2011;24:154-176.
51. Cheigh HS, Park KY. Biochemical, microbiological, and nutritional aspects of kimchi (Korean fermented vegetable products). *Crit Rev Food Sci Nutr.* 1994;34:175-203.
52. Ibe S, Kumada K, Yoshida K, Otake K. Natto (fermented soybean) extract extends the adult lifespan of *Caenorhabditis elegans*. *Biosci Biotechnol Biochem.* 2013;77:392-394.
53. Muir JG, Rose R, Rosella O, et al. Measurement of short-chain carbohydrates in common Australian vegetables and fruits by high-performance liquid chromatography (HPLC). *J Agric Food Chem.* 2009;57:554-565.
54. Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. *Med J Aust.* 2007;186:454-457.
55. Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. *J Ren Nutr.* 2005;15:77-80.
56. Miranda Alariste PV, Urbina Arronte R, Gomez Espinosa CO, Espinosa Cuevas Mde L. Effect of probiotics on human blood urea levels in patients with chronic renal failure. *Nutr Hosp.* 2014;29:582-590.
57. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. *Curr Med Res Opin.* 2009;25:1919-1930.
58. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. *Nephron.* 1996;74:349-355.
59. Guida B, Germano R, Trio R, et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. *Nutr Metab Cardiovasc Dis.* 2014;24:1043-1049.
60. Dunn SR, Simenhoff ML, Ahmed KE, et al. Effect of Oral Administration of Freeze-Dried *Lactobacillus acidophilus* on Small Bowel Bacterial Overgrowth in Patients with End Stage Kidney Disease: Reducing Uremic Toxins and Improving Nutrition. *Int Dairy J.* 1998;8:545-553.
61. Ogawa T, Shimada M, Nagano N, et al. Oral administration of *Bifidobacterium longum* in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. *Clin Kidney J.* 2012;5:373-374.
62. Ranganathan N, Ranganathan P, Friedman EA, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. *Adv Ther.* 2010;27:634-647.
63. Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. *Kidney Int.* 2001;60:1097-1105.